Microchip Biotech announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to conduct clinical trials for acute myeloid leukemia with CS43158 tablets of the company's product. CS43158 is a multi-target protein kinase inhibitor. It has both the dual effects of targeting primary driver mutations and overcoming secondary drug resistance. Compared with existing therapeutic drugs, it can further enhance antitumor activity. This matter will not have a significant impact on the company's recent performance. The clinical trial cycle for innovative drugs is long and uncertain. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.